Summary of Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian infectious disease society and the Canadian thoracic society

Canadian Respiratory Journal

Volumn 7, Issue 5, 2000, Pages 371-382

  Mandell, L A ^a   Marrie, T J ^a   Grossman, R F ^a   Chow, A W ^a   Hyland, R H ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Canada; Community acquired pneumonia; Guidelines

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; DOXYCYCLINE; GENTAMICIN; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STEROID; TETRACYCLINE; TOBRAMYCIN; UNINDEXED DRUG;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; CANADA; CLINICAL PROTOCOL; COMMUNICABLE DISEASE; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEMALE; HOSPITAL CARE; HUMAN; INCIDENCE; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NURSING HOME; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0033694307     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/412616     Document Type: Article

References (77)

1. Antimicrobial treatment of community acquired pneumonia in adults: A conference report
2. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
3. Community-acquired pneumonia in adults: Guidelines for management
4. Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
5. Canadian Task Force on the Periodic Health Examination. The periodic health examination. I. Introduction
6. Economic costs of respiratory tract infections in the United States
7. National Center for Health Statistics. National hospital discharge survey: Annual summary 1990
8. Risk factors for pneumonia in the elderly
9. Risk factors for acquiring pneumococcal infections
10. Community-acquired pneumonia requiring hospitalization: 5-year prospective study
11. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio
12. Etiology of community-acquired pneumonia in out-patients
13. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course
14. Prospective study on community-acquired pneumonia diagnosed and followed up by private practitioners
15. Serological investigation of pneumonia as it presents to the physician's office
16. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases
17. Community-acquired pneumonia: Importance of initial noninvasive bacteriologic and radiographic investigations
18. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland
19. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens
20. Community-acquired pneumonia: Impact of immune status
21. The epidemiology of community-acquired pneumonia among hospitalized adults
22. Aetiology of community-acquired pneumonia: A prospective study among adults requiring admission to hospital
23. Microbial etiology of acute pneumonia in hospitalized patients
24. Differences in etiology of pneumonias in nursing home and community patients
25. The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia
26. Pneumonia in a nursing home
27. Interim report on drug utilization review of community-acquired and nosocomial pneumonia: Clinical, bacteriological and radiological spectrum
28. Serological study of responses to selected pathogens causing respiratory tract infection in the institutionalized elderly
29. Community-acquired pneumonia in chronic obstructive pulmonary disease: A Spanish multicenter study
30. A three-year study of severe community-acquired pneumonia with emphasis on outcome
31. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit
32. Severe community-acquired pneumococcal pneumonia
33. A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission
34. Severe community-acquired pneumonia: Factors influencing need of intensive care treatment and prognosis
35. Severe community-acquired pneumonia: Etiology, prognosis, and treatment
36. Severe community-acquired pneumonia. Epidemiology and prognostic factors
37. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit
38. Bacteriology of hospital-acquired pneumonia
39. Community-acquired pneumonia
40. Severe community-acquired pneumonia: Etiology, epidemiology and prognostic factors
41. Guidelines for management of adult community-acquired lower respiratory tract infections
42. Community-acquired pneumonia: Importance of initial noninvasive bacteriologic and radiologic investigations
43. The value of routine microbial investigation in community-acquired pneumonia
44. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features
45. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination
46. Reliability of eliciting physical signs in examination of the chest
47. High-resolution computed tomography for the diagnosis of community-acquired pneumonia
48. Comparison of physician judgment and decision aids for ordering chest radiographs for pneumonia in outpatients
49. A prediction rule to identify low-risk patients with community-acquired pneumonia
50. Sputum Gram's stain in community-acquired pneumococcal pneumonia. A meta-analysis
51. Clinical value of paired sputum and transtracheal aspirates in the initial management of pneumonia
52. The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia
53. Blood cultures in adult patients released from an urban emergency department: A 15-month experience
54. Parapneumonic effusions
55. Management of complicated parapneumonic effusions
56. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia
57. Empyema thoracis during a ten-year period. Analysis of 72 cases and comparison to a previous study (1952 to 1967)
58. Serological diagnosis of Mycoplasma pneumoniae infections: A critical review of current procedures
59. Legionellosis
60. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory tract infection using the polymerase chain reaction on a single throat swab specimen
61. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia
62. The hospital admission decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study
63. The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study
64. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia
65. Clinical pathways in an acute care setting: Community-acquired pneumonia
66. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
67. Validation and application of the pneumonia prognosis index to nursing home residents with pneumonia
68. Pneumonia in residents of long-term care facilities: Epidemiology, etiology, management, and prevention
69. A double-blind, randomized, multicenter, global study in trovafloxacin with ceftriaxone plus erythromycin
70. Cross-resistance of Pseudomonas aeruginosa to ciprofloxacin, extended-spectrum beta-lactams, and aminoglycosides and susceptibility to antibiotic combinations
71. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology
72. Assessment of response to antimicrobial therapy and time to discharge in patients hospitalized with community-acquired pneumonia
73. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
74. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
75. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations
76. Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention